Fungal infections in humans range flom superficial and cutaneous (such as dermatophytoses) to deeply invasive and dissemi hated (such as candidiasis and cryptococcosis). Pathogenic fungi occur worldwide, although particular species may predominate in certain geographic areas.
In the past 20 years, fungal infections have increased dramatically--paradoxically, as a resuh of medical advances. Fungal infections occur more frequently m people whose immune system is suppressed (because of organ transplantation, cancer chemotherapy, or the human immunodeficiency vires), who have been treat- Three major groups of antifunga] compounds are in clinical use: the polyene antibiotics, the azole derivatives, and the allylamines-thiocarbamates (Fig. 1) . All interact with or inhibit ergosterol, the major sterol in the fungal plasma membrane.
[These drugs are thus ineffective against P.
carinii, which has cholesterol instead of ergosterol (5) in its membrane.]
The polyene antibiotics, produced by Streptomyces species, are fungicidal and act against more types of fungi than other antifungals (6). They bind to membrane sterols, causing increased membrane permeability, leakage of cytoplasmic contents, and cell death. The clinically useful polyenes--amphotericin B, nystatin, and pimaricin--have a higher affinity for ergosterol than its mammalian counterpart, cholesterol, thus limiting their toxicity in mammalian cells; nephrotoxicity is the major side effect. Amphotericin B, the only polyene used in invasive mycoses, is particularly appropriate for the treatment of deeply invasive mycoses in severely immunocompromised patients, in spite of its considerable acute and chronic toxicity. The serious side effects may be reduced by new delivery systems, such as liposomes, lipid complexes, and colloidal dispersions (7). The azole derivatives are completely synthetic, and man}, new compounds in this class have become available (8) . In general, the broad antifungal activity of azoles includes most yeasts and filamentous fungi. Depending on whether the azole has two or three nitrogens in the five-membered azole ring, it is classified as an imidazole or triazole. The azoles act primarily on ergosterol biosynthesis at the C-14 demethylation step, a cytochrome P-450-dependent reaction (Fig.  2) . The resulting ergosterol depletion and accumulation of methylated sterols interferes with the ns "bulk" functions of ergos- functions of ergosterol and affect cell growth and proliferation (9) . The overall effect is fungistatic rather than fungicidal, limiting the utility of these drugs. Nevertheless, azoles (ketoconazole, fluconazole, and itraconazole) are being used more frequently in the treatment of systemic mycoses, even in severely immunosuppressed patients. The older imidazoles also interfere with ergosterol functions but, in addition, can interact with and damage the cell membrane directly; they are consequently fungicidal and toxic and therefore used only topically (8) . The newer antifungal~azoles do not produce serious toxicity; however, they influence the endocrine system by inhibiting mammalian cytochrome P-450-dependent enzymes that synthesize steroid hormones. These effects are more pronounced with imidazoles than with triazoles; ketoconazole, for instance, inhibits testosterone synthesis at 100 times lower concentration than fluconazole (10) . clinical use, naftifine (topical) and terbinafine (oral), and one thiocarbamate, tolnaftate (topical) (11) . All three inhibit squalene epoxidase which, together with oxidosqualene cyclase, cyclizes squalene to lanosterol (Fig. 2) . The resulting ergosterol depletion and squalene accumulation affect membrane structure and functions such as nutrient uptake. Squalene epoxidase is not a cytochrome P-450 enzyme, and thus this class of compounds is less toxic than the azoles. Because of their poor pharmacokinetics, these compounds work only against dermatophytes, although squalene epoxidase is ubiquitous and allylamines have broad antifungal activity in vitro. Less commonly used drugs include the mo> pholines: For example, amorolfine, which is used in the topical treatment of nail infections, also acts on the ergosterol pathway (•2). Morpholines inhibit two steps in the ergosterol pathway, k14 reductase and lXv-eX 8 tsomerase (Fig. 2) . Other targets tn the ergosterol pathway are oxidosqualene cyclase and g~24 methyltransferase (13), the latter being unique to ergosterol synthesis and thus a particularly attractive target. However, even targets with counterparts in the cholesterol pathway may be clinically useful, because contrary to fungi, which have no uptake system for sterols. mammalian cells can take up dietary chdesterol via the low density lipoprotein (LDL) pathway (14) . Targers in the early steps of ergosterol synthesis include hydroxymethyl glutaryl coenzyme A (CoA) and mevalonic acid synthesis (13) , although so far inhibitors of these steps do not have antifungal activity--probably because they cannot penetrate the membrane.
The fluoropyrimidine 5-fluorocytosine (5-FC) has a limited activity spectrum and is mainly used in combination with amphotericin B in cryptococcal meningitis (15) . It is deaminated to 5-fluorouracil (5-FU), converted to the nucleoside triphosphate, and incorporated into RNA where it causes miscoding. In addition, 5-FU is converted to deoxynucleoside, which inhibits thymidylate synthase and thereby DNA biosynthesis.
The fungat cell wall, a structure essential to fungi that has functions similar to its bacterial counterpart and that is lacking m mammalian cells, would seem to be an ideal target for antifungal agents. Inhibitors of the biosynthesis of two important cell wall components, glucan and chitin, already exist. Polyoxins and the structurally related nikkomycins (both consist of a pyrimidine nucleoside linked to a peptide moiety) inhibit chitin synthase competitively, presumably acting as analogs of the substrate uridine diphosphate (UDP)-N-acetylglucosamine (chitin is an N-acetylglucosamine homopolymer), causing inhibition of septation and osmotic lysis (16) . Unfortunately, the target of polyoxins and nikkomycins is in the inner leaflet of the plasma membrane; they are taken up by a dipeptide permease, and thus peptides in body fluids antagonize their transport. Appropriate polyoxin derivatives that bypass peptide transport have been synthesized (•6). Another hopeful development is the observed synergy between chitin synthase inhibitors and glucan or ergosterol synthesis inhibitors (17) , although its clinical significance is not 
carinii (19).
Topoisomerase I and II control the topological state of DNA so that it can undergo replication, transcription, repair, and chromosomal segregation (20) . The success of topoisomerase inhibitors in antibacterial and anticancer chemotherapy has made fungal topoisomerases particularly attractive drug targets (20) . However, it is not yet known whether fungal topoisomerases have exploitable differences relative to their mammalian counterparts.
Elongation factor 3 (EF-3), a 125-kD protein, participates in fungal but not mammalian protein synthesis (21) and is another promising target. It is present in most fungi and is essential for viability--disruption of its gene is lethal (21) . It is specifically required by the yeast 40S ribosomal subunit, although its exact function in the elongation cycle is unclear. A major drawback for rational drug design is the absence of known EF-3 inhibitors.
The success of the antibacterial agents trimethoprim and sulfomethoxazole in treating and P. carinii pneumonia has validated their sites of action in the folate pathway as drug targets for this organism, although nor for other fungi. Toxicity considerations would preclude DNA itself as being an antifungal target, although it is the likely target of the antipneumocystis drug pentamidine (22) . After the discovery of cispentacin which inhibits homoserine dehydrogenase (23) , the possibility of interfering with amino acid synthesis emerged, although available information may not yet be sufficient to launch a synthetic, rational drug design program. Ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis and a favorite target for growth inhibition in cancer chemotherapy (24) , may be another antifungal target. Microtubule aggregation--the target for griseofulvin, the agricultural fungicide benomyl, and the anticancer drugs vincristme, vinblastine, and taxol (25) also merits reexamination as a possible target for clinical antifungals. More speculative means to combat fungi include inhibiting protease activity, decreasing adhesion through alternate ligands, and preventing phase transition to the more invasive form, or preventing virulence in general, through effects on signal transduction.
The recent surge in the use of antifungal agents, particularly azoles, is shifting the population of fungal pathogens toward species that are intrinsically resistant (for example, non-albicans Candida species) and is selecting resistant strains of susceptible species. Despite recent progress, problems m detection and susceptibility testing continue to affect treatment. Permeability constraints, far less rigorously studied in fungi than in bacteria, have prevented potent inhibitors of promising targets from becoming potent antifungals. New approaches and chemical entities are urgently needed, since the conditions that led to the emergence of fungal infections in the first place are likely to persist in the future. 
